



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/553,807	02/02/2006	Bernard Fromenty	125649	7793
25944 7590 08/11/2009 OLIFF & BERRIDGE, PLC P.O. BOX 320850 ALEXANDRIA, VA 22320-4850				
EXAMINER				
POLANSKY, GREGG				
ART UNIT		PAPER NUMBER		
1614				
MAIL DATE		DELIVERY MODE		
08/11/2009		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/553,807

Applicant(s)

FROMMENTY ET AL.

Examiner

GREGG POLANSKY

Art Unit

1614

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 06 April 2009.
2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1,3,5-13,15-20,22-28 and 37-43 is/are pending in the application.
4a) Of the above claim(s) 5-7,10-13 and 22-27 is/are withdrawn from consideration.
5) ☒ Claim(s) 1,3,15-19,37-39 and 43 is/are allowed.
6) ☒ Claim(s) 8,9,40 and 41 is/are rejected.
7) ☒ Claim(s) 20,28 and 42 is/are objected to.
8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)
3) ☐ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____
4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
5) ☐ Notice of Informal Patent Application
6) ☐ Other: _____

DETAILED ACTION

Status of Claims

1. Applicants' response, filed 4/06/2009, to the Office Action mailed 12/04/2008 is acknowledged. Applicants canceled Claims 2, 4, 14, 21, and 29-36, amended Claims 1, 3, 8, 9, 15, 20, 28, and 37, added Claims 38-43, and presented arguments in response to the Office Action.
2. Claims 1, 3, 5-13, 15-20, 22-28, and 37-43 are pending.
3. Claim 1, 3, 8, 9, 15-20, 28, and 37-43 are presently under consideration.
4. Applicants' arguments have been fully considered and are deemed to be persuasive. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application.

Claim Objections

5. Claim 20 is objected to under 37 CFR 1.75 as being a substantial duplicate of Claim 1. Claims 28 and 42 are objected to under 37 CFR 1.75 as being a substantial duplicate of Claims 15 and 38, respectively (because Claims 28 and 42 depend from Claim 20 and have essentially the same subject as Claims 15 and 38, respectively). When two claims in an application are duplicates or else are so close in content that they both cover the same thing, despite a slight difference in wording, it is proper after

allowing one claim to object to the other as being a substantial duplicate of the allowed claim. See MPEP § 706.03(k).

Claim Rejections - 35 USC § 112

6. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

7. Claims 8 and 40 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 8 recites "A method for treating or reducing the risk of developing an **obese condition...**" (emphasis added), which renders the claim indefinite. It is unclear what clinical conditions fall within the scope of the instantly claimed subject, making it impossible to ascertain with reasonable precision the metes and bounds of the claim. Although the claim is interpreted in light of the Specification, limitations from the Specification are not read into the claims. See *In re Van Geuns*, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993).

8. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

9. Claims 9 and 41 are rejected under 35 U.S.C. 112, first paragraph, because the Specification, while being enabling for a treatment for the reduction of the gain of body fat in an animal in need thereof, does not reasonably provide enablement for a treatment for the inhibition of the gain of body fat in an animal in need thereof. Inhibition can be interpreted as being synonymous with prevention. The Specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims. This is a Scope of Enablement rejection.

The factors to be considered in determining whether a disclosure meets the enablement requirements of 35 U.S.C. 112, first paragraph, have been described in *In re Wands*, 858 F.2d 731, 8 USPQ2d 1400 (Fed. Cir., 1988). The court in *Wands* states, "Enablement is not precluded by the necessity for some experimentation, such as routine screening. However, experimentation needed to practice the invention must not be undue experimentation. The key word is 'undue', not 'experimentation'" (*Wands*, 8 USPQ2d 1404). Clearly, enablement of a claimed invention cannot be predicated on the basis of quantity of experimentation required to make or use the invention. "Whether undue experimentation is needed is not a single, simple factual determination, but rather is a conclusion reached by weighing many factual considerations" (*Wands*, 8 USPQ2d 1404). Among these factors are: (1) the nature of the invention; (2) the breadth of the claims; (3) the state of the prior art; (4) the predictability or unpredictability of the art; (5) the relative skill of those in the art; (6) the amount of direction or guidance presented; (7) the presence or absence of working examples; and (8) the quantity of experimentation necessary.

While all of these factors are considered, a sufficient amount for a *prima facie* case is discussed below.

(1) The nature of the invention and (2) the breadth of the claims:

The instant claims are drawn to a method of treatment for the reduction or inhibition of the gain of body fat in an animal in need thereof, by administering an effective amount of β -aminoisobutyric acid, an organic or inorganic salt thereof, or an

ester thereof. The claims are broad since they encompass the inhibition of a gain of body fat. Inhibition can be reasonably interpreted as prevention.

(3) The state of the prior art:

The Merck Manual (previously cited) teaches there are many factors that influence weight gain, including: genetic and environmental factors, physical inactivity, alcohol consumption, socioeconomics, menopause in women, stress, polycystic ovary syndrome, pharmaceuticals, and smoking cessation. See page 2.

(4) The predictability or unpredictability of the art and (5) the relative skill of those in the art:

The relative skill of those in the art of pharmacology and medicine and the unpredictability of the pharmacological and biological arts are very high. In fact, the courts have made a distinction between mechanical elements, which function the same in different circumstances, yielding predictable results, and chemical and biological compounds, which often react unpredictably under different circumstances. *Nationwide Chem. Corp. v. Wright*, 458 F. supp. 828, 839, 192 USPQ 95, 105(M.D. Fla. 1976); *Aff'd* 584 F.2d 714, 200 USPQ 257 (5th Cir. 1978); *In re Fischer*, 427 F.2d 833, 839, 166 USPQ 10, 24(CCPA 1970). Thus, the physiological activity of a chemical or biological compound is considered to be an unpredictable art. Likewise, the physiological or pharmaceutical activity of inhibition/prevention of the gain of body fat, particularly with

regard to the multitude of factors which influence the gain of body fat, is an unpredictable art.

Thus, it is not understood how one skilled in the art can reasonably expect that the instant compound can be administered in order to have the inhibitive/preventative effect.

(6) The amount of direction or guidance presented and (7) the presence or absence of working examples:

The Specification has provided guidance and working examples for the use of β -aminoisobutyric acid for reducing weight gain and reduction of triglycerides in mice.

(8) The quantity of experimentation necessary:

The amount of guidance or direction needed to enable the invention is inversely related to the degree of predictability in the art. *In re Fisher*, 839, 166 USPQ 24. Thus, although a single embodiment may provide broad enablement in cases involving predictable factors, such as mechanical or electrical elements, in cases involving unpredictable factors, such as most chemical reactions and physiological activity, more teaching or guidance is required. *In re Fisher*, 427 F.2d 839, 166 USPQ 24; *Ex Parte Hitzeman*, 9 USPQ 2d 1823. For example, the Federal Circuit determined that, given the unpredictability of the physiological activity of RNA viruses, a specification requires more than a general description and a single embodiment to provide an enabling disclosure for a method of protecting an organism against RNA viruses. *In re Wright*, 999 F.2d 1562-63, 27 USPQ2d 1575.

Conclusion

10. Claims 8, 9, 40, and 41 are rejected.
11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to GREGG POLANSKY whose telephone number is (571)272-9070. The examiner can normally be reached on Mon-Thur 9:30 A.M. - 7:00 P.M. EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin H. Marschel can be reached on (571) 272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Gregg Polansky/
Examiner, Art Unit 1614

Application/Control Number: 10/553,807

Page 8

Art Unit: 1614

/Ardin Marschel/

Supervisory Patent Examiner, Art Unit 1614